Bluefin Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bluefin Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$1.32M	–	185
2025 Q1	$1.32M	Buy	+10,000	New	+$1.25M	0.95%	21
2019 Q4	–	Sell	-42,649	Closed	-$512K	–	757
2019 Q3	$319K	Buy	+42,649	New	+$409K	0.05%	223

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bluefin Capital Management's ITCI Position: Q2 2025 in Review

Bluefin Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 10,000 shares — an estimated $1.32M sold.

Bluefin Capital Management first reported a position in ITCI in Q3 2019 and held it in 2 quarters. The position peaked at $1.32M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Bluefin Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Bluefin Capital Management sold 10,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.32M.
Bluefin Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 2 quarters.
Bluefin Capital Management's Intra-Cellular Therapies Inc. position peaked at $1.32M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Bluefin Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.